Market Intelligence, Clinical Progress, and High-Purity Reagents for Atypical Chemokine Receptor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CXCR7/ACKR3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Full-Length Lentivirus) | CXCR7/ACKR3 Full-Length Lentivirus Premade Particles. HEK293 Expressed, Native Conformation, Titer >1×10⁸ TU/ml, Endotoxin <1 EU/µg. For stable cell line generation. | View CXCR7 Products |
| Antigen (ECD-Fc Fusion Protein) | CXCR7/ACKR3 ECD-Fc Fusion Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View CXCR7 Products |
| Gene Delivery / ORF Clone | CXCR7 Promise-ORF Clone. Codon-optimized for mammalian expression, C-terminal GFP/RFP optional, Sequence Verified. | View CXCR7 Products |
| Benchmark Ab | Anti-CXCR7 Benchmark Antibody. Recombinant positive control. Sequence Verified. High Purity (>95%). | View CXCR7 Products |
| Validator | CXCR7 siRNA Set. For knockdown verification. Sequence Verified, HPLC purified. | View CXCR7 Products |
| Related Target: CXCR4 | CXCR4. Shared ligand receptor; critical for combination pathway analysis and counter-screening. | View CXCR4 Products |
| Related Target: CXCL12 | CXCL12. Primary endogenous ligand for competitive binding assays. | View CXCL12 Products |
| Related Target: CXCR3 | CXCR3. Off-target liability panel for selectivity profiling. | View CXCR3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native GPCR Conformation & Membrane Topology | Lentivirus Stable Cell Lines (HEK293). Full-length ORF with native glycosylation. Cell-based assays are the only way to preserve conformation. |
| Ligand Scavenging & β-arrestin Recruitment | High-expression Lentivirus particles enable Flow Cytometry, BRET/PathHunter β-arrestin recruitment, and internalization assays. |
| Cross-species Cyno/Mouse/Human Evaluation | Ortholog proteins available with >95% purity. Sequence Verified for preclinical translation. |
| CXCR4 Subfamily Counter Screening | Homolog panel proteins (CXCR4, CXCR3) strictly verified by mass spec. Avoid off-target binding to shared CXCL12 axis. |
| Lack of Controls | Clinical Benchmark Antibodies (Reference Biosimilars) included. |
| False Positives | Validated siRNA included for specificity checks. |
Live CXCR7/ACKR3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
CXCR7 (now officially renamed ACKR3) is an atypical chemokine receptor that functions as a decoy receptor, regulating extracellular CXCL12 and CXCL11 levels without classical G-protein signaling. The race for CXCR7/ACKR3 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to next-generation biologics (nanobodies, bispecifics) and small-molecule modulators. As first-generation assets targeting the CXCL12 axis mature, the next wave of R&D is targeting stromal-tumor crosstalk, combination regimens with CXCR4 inhibitors, and tissue-specific scavenger blockade in fibrosis and immuno-oncology. The receptor's role in tumor microenvironment modulation is drawing significant investment, particularly in solid tumors and fibrotic diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist | ChemoCentryx (Preclinical), emerging Biotech & Academia | Solid Tumors, Fibrosis | Whole-cell binding & β-arrestin recruitment on Lentivirus-stable lines (preserves conformation) |
| Monoclonal Antibody / Nanobody | Academic/Biotech, early-stage Biologics Developers | Oncology, Immuno-Oncology | Cell-based Flow Cytometry for binding affinity; cross-species binding (Human/Cyno/Mouse ECD orthologs) |
| ADC / Internalizing Biologic | Oncology-Focused Biotech | ACKR3+ Stromal Cancers | Internalization Assay using High-expression Lentivirus for Flow Cytometry |
| Bispecifics | Early R&D | Immunotherapy | Heterodimer validation requiring cross-reactive controls |